Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RuL2
- Development stage
- Preclinical
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
RuL2 is a ruthenium complex synthesized with an α-amino acid, l-alanine, and 2,3-dihydroxybenzaldehyde derived Schiff base. It has demonstrated significant binding towards human serum albumin (HSA) and exhibits concentration-dependent cytotoxicity in human hepatocellular carcinoma (HepG2) cell lines. Its cytotoxic effects are mediated via protein binding and the generation of reactive oxygen species (ROS).
Beyond the preview
Go deeper on RuL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RuL2.